Validation of multiple data sets shows that ABCA6, PLCL1, and PLOD2 can jointly predict disease-free survival and overall survival and may serve as potential targets for treating GC, providing a basis for developing targeted drugs. Here, PLCL1 is linked to gastric cancer.